Post-marketing surveillance of AVIGAN tablets 200mg (SFTS)

Post-marketing surveillance of AVIGAN tablets 200mg (All-Case Surveillance) - Severe Fever with Thrombocytopenia Syndrome -

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT2031240539

Enrollment

340

Registered

2024-12-17

Start date

2024-08-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe Fever with Thrombocytopenia Syndrome

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients treated with AVIGAN tablets 200 mg

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Incidence of adverse drug reactions Incidence of serious adverse events	—

Secondary

Measure	Time frame
Mortality rate (by patient demographics and disease characteristics) [at the time of discontinuation of AVIGAN tablets 200 mg or discharge (including death), cumulative mortality rate up to Day 28 after the start of administration]	—

Contacts

Public ContactManager of Post-marketing surveillance

FUJIFILM Toyama Chemical Co., Ltd.

tc-avg@fujifilm.com+81-3-5579-5768

Outcome results